论文部分内容阅读
为了探讨终末期肾病(ESRD)患者血清成纤维细胞生长因子23(FGF-23)水平与心血管钙化的关系。我们选取了2015年9月~2016年5月在我院各科室接受治疗的ESRD患者68例为实验组,选取46例健康成年人为对照组。使用超声和腹部X线平片对心血管和腹主动脉血管钙化情况进行评定,同时测量成纤维细胞生长因子23(FGF-23)、血清肌酐(Scr)、钙(Ca)、磷(P)、碱性磷酸酶(ALP)、总胆固醇(TC)、三酰甘油(TG)、血红蛋白(HB)、甲状旁腺激素(i PTH)各项指标的含量。ESRD组患者FGF-23水平高于对照组,差异有统计学意义(p<0.05),ESRD组患者FGF-23水平与Scr、P、iPTH、ALP呈正相关(r=0.423~0.687),与Ca、TC、TG、HB无相关性(r=-0.014~-0.113)。钙化组患者FGF-23水平高于非钙化组,差异有统计学意义(p<0.05)。ESRD患者血清FGF-23水平的升高与心血管钙化的发生发展密切相关。
To investigate the relationship between serum fibroblast growth factor 23 (FGF-23) levels and cardiovascular calcification in patients with end-stage renal disease (ESRD). We selected 68 cases of ESRD patients treated in our hospital from September 2015 to May 2016 as the experimental group and 46 healthy adults as the control group. Cardiovascular and abdominal aortic vascular calcifications were assessed by ultrasound and abdominal plain radiography. FGF-23, Scr, Ca and P were measured at the same time. , Alkaline phosphatase (ALP), total cholesterol (TC), triglyceride (TG), hemoglobin (HB) and parathyroid hormone (i PTH) The level of FGF-23 in ESRD group was higher than that in control group (p <0.05). The level of FGF-23 in ESRD group was positively correlated with Scr, P, iPTH and ALP (r = 0.423-0.687) , TC, TG, HB no correlation (r = -0.014 ~ -0.113). The level of FGF-23 in calcification group was higher than that in non-calcification group, the difference was statistically significant (p <0.05). ESRD patients with elevated serum levels of FGF-23 and the development of cardiovascular calcification is closely related.